It was observed that silencing CEACAM6 significantly reduced the proliferation and sensitivity of CRC cells to 5-FU, but not to oxaliplatin, even under ALDOB overexpression (Fig. 5B–D). Here, ALDOB is linked to colorectal carcinoma.